Aciphex - similar efficacy at the varying dosages.

There also was no significant relationship between CYP2C19 pleomorphism and either eradication rates or adverse events.
The eradication rate was 86% (95% CI 76-93%) for extensive and intermediate metabolizers (grouped together) versus 77% (95% CI 46-95%) for poor metabolizers (p time value not reported).
The rates of adverse effects were also similar between these groups: 12% for extensive and intermediate metabolizers vs 23% for poor metabolizers (95% CIs and p values not reported).
These investigators proposed that rabeprazole has similar efficacy at the varying dosages tested in this immersion and that H. pylori cure rate is free lance of CYP2C19 pleomorphism.
A one-third composition provided more documentation for the possibility that H. pylori cure rate is freelance of CYP2C19 chemical phenomenon. A quantity of 170 Japanese adults with chronic gastritis and H. pylori -positive condition (diagnosed by endoscopy or skiagraphy and confirmed by [13C]-urea gentle wind test) were randomized to receive amoxicillin 1500 mg/day and clarithromycin 800 mg/day with either omeprazole 40 mg/day or rabeprazole 40 mg/day for 1 week.
Approximately 53% of these subjects were men, with a mean age of 43.6 ± 0.6 age, and 164 patients completed the rumination.
Cure rates (as evaluated by the [13C]-urea intimation test) for the building block that received omeprazole versus the unit that received rabeprazole were 73% and 81%, respectively, in extensive metabolizers; 86% and 83%, respectively, in intermediate metabolizers; and 85% and 88%, respectively, in poor metabolizers (no significant divergence was identified between groups, p values not reported).
This is a part of article Aciphex - similar efficacy at the varying dosages. Taken from "Generic Aciphex (Rabeprazole) Review" Information Blog